Everest Medicines VELSIPITY Manufacturing Gets China Priority Review
Everest Medicines' application for localized manufacturing of VELSIPITY in China has been accepted by the CDE and granted Priority Review. Production is slated to commence in 2027 with an annual capacity of up to 50 million tablets.